How Leiomodin1 helps form strong new blood vessels in low-oxygen limb disease
The Role of Leiomodin1 in Hypoxic Neovessel Maturation
This project will see if the protein Leiomodin1 helps new blood vessels mature and restore blood flow for people with peripheral artery disease, especially those with diabetes-related circulation problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11332978 on NIH RePORTER |
What this research studies
You have peripheral artery disease when blood flow to your leg is reduced and new vessels that form are often fragile. Researchers are studying the gene Leiomodin1 (LMOD1), which their mouse work links to stronger, less leaky vessels. They will use laboratory experiments and animal models and analyze human-relevant samples and data to understand how LMOD1 controls vessel maturation in low-oxygen limb tissue. The team aims to find molecular steps that could be targeted to grow stable vessels and improve leg blood flow.
Who could benefit from this research
Good fit: Ideal candidates are adults with peripheral artery disease, especially those with poor leg blood flow or diabetes-related circulation problems who might be interested in future clinical studies.
Not a fit: People without arterial causes of leg symptoms, children, or patients whose conditions are unrelated to PAD are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, this work could lead to treatments that build more stable new arteries and improve blood flow to the legs, reducing pain, nonhealing wounds, and risk of limb loss.
How similar studies have performed: Past attempts to promote new vessel growth in PAD have had limited clinical success, and targeting LMOD1 is a newer approach with encouraging animal findings but not yet proven in people.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Nanda, Vivek — University of Alabama at Birmingham
- Study coordinator: Nanda, Vivek
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.